Results: 2

1.
Figure 1

Figure 1. From: Sulindac and Sulindac Metabolites in Nipple Aspirate Fluid and Effect on Drug Targets in a Phase I Trial.

Change in nipple aspirate biomarker levels of PGEM and GDF15. Subject-level change in PGEM normalized by total protein is shown for (A) 150 mg q.d. sulindac and (B) 150 mg b.i.d. sulindac. Subject-level change in GDF15 normalized by total protein is shown for (C) 150 mg q.d. sulindac and (D) 150 mg b.i.d. sulindac. Note that for PGEM, 0 of 10 samples in the 150 mg q.d. dose and 3 of 11 in the 150 mg b.i.d. dose were undetectable (0) at baseline and for GDF15, 4 of 11 in the 150 mg q.d. dose and 3 of 11 in the 150 mg b.i.d. dose at baseline were undetectable.

Patricia A. Thompson, et al. Cancer Prev Res (Phila). 2010 January;3(1):101-107.
2.
Figure 2

Figure 2. Change in CRP according to baseline level. From: Sulindac and Sulindac Metabolites in Nipple Aspirate Fluid and Effect on Drug Targets in a Phase I Trial.

Box plots showing the change in mean serum hsCRP levels for all subjects and stratified by baseline hsCRP level. Among women whose baseline CRP values were considered above normal (>1.0 mg/L; n = 15), a statistically significant decrease of 1.76 mg/L was observed (p =0.02).

Patricia A. Thompson, et al. Cancer Prev Res (Phila). 2010 January;3(1):101-107.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk